Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Everyone should be eating protein, but Dr. Sowa says it’s "very, very important" when you’re on a weight loss journey. “It’s ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight loss drug trial ... s own Wegovy and Ozempic, and Eli Lilly’s ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...